Table 3

Estimation of tumor content by segmentation in the CRL-2324 dilution series (data set 3)

Hemizygous loss 18q21.32-q22.3

Single copy gain 13q11-q12.3

CNN LOH 13q21.31-qter§




Tumor (%)*

Expected mBAF

Observed mBAF

Tumor (%)

Expected mBAF

Observed mBAF

Tumor (%)

Expected mBAF

Observed mBAF

Tumor (%)


0

0.5

0.53

12

0.5

0.53

15

0.5

0.53

6

10 (7-12)

0.53

0.53

11

0.52

0.53

12

0.55

0.54

7

14 (10-17)

0.54

0.53

12

0.53

0.53

12

0.57

0.55

9

21 (17-26)

0.56

0.55

18

0.55

0.54

16

0.6

0.58

16

23 (18-28)

0.56

0.6

32

0.55

0.56

28

0.62

0.64

28

30 (24-35)

0.59

0.58

27

0.57

0.55

21

0.65

0.62

24

34 (28-40)

0.60

0.59

31

0.57

0.55

23

0.67

0.64

29

45 (38-51)

0.65

0.61

37

0.59

0.56

27

0.72

0.67

33

47 (40-54)

0.65

0.65

46

0.6

0.57

35

0.74

0.71

42

50 (43-57)

0.67

0.64

43

0.6

0.57

30

0.75

0.7

39

79 (74-83)

0.83

0.84

81

0.64

0.6

51

0.9

0.89

77

100

1

0.93

93

0.67

0.65

88

1

0.95

89


*95% confidence interval within parentheses. Hemizygous loss chr18:54400001-71300000. Single copy gain chr13:16000001-31100000. §Copy number neutral LOH chr13:60500001-114142980.

Staaf et al. Genome Biology 2008 9:R136   doi:10.1186/gb-2008-9-9-r136

Open Data